Table 1.
Diagnosis, baseline characteristics, and clinical presentation of patients presenting with acute coronary syndromes stratified by CYP3A4 metabolised statin use
| All patients with acute coronary syndromes | ||||
| Clopidogrel + no statin (n = 180) | Clopidogrel + CYP3A4 (n = 561) | Clopidogrel + non-CYP3A4 (n = 91) | p Value* | |
| Diagnosis | ||||
| ST elevation MI | 44 (24.4%) | 136 (24.2%) | 15 (16.5%) | 0.10 |
| Non-ST elevation MI | 109 (60.6%) | 335 (59.7%) | 57 (62.6%) | 0.59 |
| Unstable angina | 27 (15%) | 90 (16%) | 19 (20.9%) | 0.25 |
| Demographics | ||||
| Age (years) | 64.7 (13.8) | 62.2 (12.9) | 59.7 (12.5) | 0.08 |
| Male sex | 116 (64.4%) | 390 (69.5%) | 63 (69.2%) | 0.95 |
| Body mass index | 28.4 (6.3) | 29.3 (5.8) | 29.1 (5.5) | 0.76 |
| Prior angina | 86 (47.8%) | 265 (47.4%) | 57 (63.3%) | <0.01 |
| Prior MI | 70 (39.1%) | 219 (39.3%) | 38 (42.2%) | 0.60 |
| Prior stroke | 21 (11.8%) | 56 (10.1%) | 8 (8.9%) | 0.73 |
| Prior heart failure | 37 (20.6%) | 65 (11.6%) | 11 (12.1%) | 0.89 |
| Previous coronary intervention | 44 (24.6%) | 183 (32.9%) | 31 (34.8%) | 0.72 |
| Previous bypass surgery | 34 (18.9%) | 122 (21.8%) | 22 (24.7%) | 0.54 |
| Smoking (current or former) | 101 (56.1%) | 358 (64.2%) | 59 (65.6%) | 0.79 |
| Diabetes | 59 (32.8%) | 154 (27.5%) | 26 (28.6%) | 0.82 |
| Hypertension | 149 (82.8%) | 456 (81.3%) | 66 (72.5%) | 0.05 |
| Hyperlipidaemia | 91 (50.6%) | 493 (87.9%) | 72 (79.1%) | 0.02 |
| Clinical presentation | ||||
| Positive cardiac biomarkers | 152 (84.4%) | 464 (82.7%) | 72 (79.1%) | 0.40 |
| Serum creatinine (μmol/l) | 124 (115) | 106 (71) | 97 (35) | 0.42 |
| ECG | ||||
| New ST segment depression | 43 (23.9%) | 134 (23.9%) | 14 (15.4%) | 0.07 |
| New significant Q wave | 11 (6.1%) | 23 (4.1%) | 3 (3.3%) | 0.71 |
Data are mean (SD) or number (%).
CYP3A4 metabolised statins: lovastatin, simvastatin, cerivastatin, and atorvastatin. Non-CYP3A4 metabolised statins: pravastatin, fluvastatin, rosuvastatin.
*Comparisons between patients who received CYP3A4 statin versus a non-CYP3A4 statin with clopidogrel. Categorical variables were compared with χ2 tests and continuous variables, with t tests.
MI, myocardial infarction